Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Nov;31(6):e13747.
doi: 10.1111/ecc.13747. Epub 2022 Nov 6.

Eribulin for the treatment of advanced breast cancer: A prospective observational registry study

Laura Kenny  1   2 , Mark Beresford  3 , Ian Brown  4 , Vivek Misra  5 , Hartmut Kristeleit  6
Affiliations
Observational Study

Eribulin for the treatment of advanced breast cancer: A prospective observational registry study

Laura Kenny et al. Eur J Cancer Care (Engl). 2022 Nov.

Abstract

Objective: Eribulin treatment improved overall survival with predictable toxicities in phase 3 trials of patients with previously treated, locally advanced/metastatic breast cancer. This study (NCT02443428) prospectively observed eribulin-treated patients in real-world clinical practice.

Methods: This observational multicentre registry study enrolled 76 patients with locally advanced/metastatic breast cancer who had ≤2 prior chemotherapeutic regimens for advanced disease. Eribulin was administered at a 1.23 mg/m2 dose (days 1 and 8 of every 21-day cycle). Adverse events (AEs) were monitored and effectiveness was assessed per local practice.

Results: AEs occurred in 98.7% of patients; 88.2% had eribulin-related AEs. The most common AEs were fatigue (64.5%), alopecia (36.8%), nausea (35.5%) and constipation (30.3%). Serious AEs occurred in 42.1% of patients. The most common grade 3/4 AEs were neutropenia (9.2%), febrile neutropenia (9.2%), dyspnoea (5.3%) and pleural effusion (5.3%). No fatal AEs occurred. Dose reductions occurred in 31.6% of patients, 42.1% experienced dose delays and 9.2% discontinued due to worsening condition. There were complete responses in 2.6% and partial responses in 15.8% of patients. Median time to progression and overall survival were 4.0 and 8.3 months, respectively.

Conclusion: Eribulin was well tolerated in real-world clinical practice, comparable to safety and effectiveness reported in other clinical trials.

Keywords: adverse events; effectiveness; eribulin; metastatic; real-world study.

PubMed Disclaimer

Conflict of interest statement

Laura Kenny has served on advisory boards for Celgene and Novartis and given educational presentations sponsored by Lilly and Pfizer.

Mark Beresford has received honoraria and lecture fees from Eisai, Roche, Lilly, Pfizer and Novartis.

Ιan Brown is an employee of Eisai, Ltd.

Vivek Misra and Hartmut Kristeleit have received honoraria and consultancy fees from Eisai, Ltd, for educational lectures, presentation of audit findings and for attendance at Advisory Boards.

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier estimation of time to progression. Tumour response was assessed according to the physician's usual practice rather than being protocol driven. Data shown are for the overall safety population (N = 76). CI, confidence interval
FIGURE 2
FIGURE 2
Kaplan–Meier estimation of overall survival. Data shown are for the overall safety population (N = 76). CI, confidence interval
See this image and copyright information in PMC

References

    1. Adamo, V. , Ricciardi, G. R. R. , Giuffrida, D. , Scandurra, G. , Russo, A. , Blasi, L. , Spadaro, P. , Iacono, C. , Soto Parra, H. J. , Savarino, A. , Ferraú, F. , Zerilli, F. , Verderame, F. , Butera, A. , Santangelo, C. , Franchina, V. , & Caruso, M. (2019). Eribulin mesylate use as third‐line therapy in patients with metastatic breast cancer (VESPRY): A prospective, multicentre, observational study. Therapeutic Advances in Medical Oncology, 11, 1758835919895755. 10.1177/1758835919895755 - DOI - PMC - PubMed
    1. Cardoso, F. , Costa, A. , Senkus, E. , Aapro, M. , André, F. , Barrios, C. H. , Bergh, J. , Bhattacharyya, G. , Biganzoli, L. , Cardoso, M. J. , Carey, L. , Corneliussen‐James, D. , Curigliano, G. , Dieras, V. , el Saghir, N. , Eniu, A. , Fallowfield, L. , Fenech, D. , Francis, P. , … Winer, E. (2017). 3rd ESO‐ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Annals of Oncology, 28, 16–33. 10.1093/annonc/mdw544 - DOI - PMC - PubMed
    1. Cardoso, F. , Fallowfield, L. , Costa, A. , Castiglione, M. , Senkus, E. , & ESMO Guidelines Working Group . (2011). Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Annals of Oncology, 22, vi25–vi30. 10.1093/annonc/mdr372 - DOI - PubMed
    1. Cortes, J. , O'Shaughnessy, J. , Loesch, D. , Blum, J. L. , Vahdat, L. T. , Petrakova, K. , Chollet, P. , Manikas, A. , Diéras, V. , Delozier, T. , Vladimirov, V. , Cardoso, F. , Koh, H. , Bougnoux, P. , Dutcus, C. E. , Seegobin, S. , Mir, D. , Meneses, N. , Wanders, J. , & Twelves, C. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open‐label randomised study. Lancet, 377, 914–923. 10.1016/S0140-6736(11)60070-6 - DOI - PubMed
    1. Dybdal‐Hargreaves, N. F. , Risinger, A. L. , & Mooberry, S. L. (2015). Eribulin mesylate: Mechanism of action of a unique microtubule‐targeting agent. Clinical Cancer Research, 21, 2445–2452. 10.1158/1078-0432.CCR-14-3252 - DOI - PMC - PubMed

Publication types